Featured Publications
Generalizing the per-protocol treatment effect: The case of ACTG A5095
Lu H, Cole S, Hall H, Schisterman E, Breger T, Edwards J, Westreich D. Generalizing the per-protocol treatment effect: The case of ACTG A5095. Clinical Trials 2018, 16: 52-62. PMID: 30326736, PMCID: PMC6693502, DOI: 10.1177/1740774518806311.Peer-Reviewed Original ResearchConceptsFour-drug antiretroviral regimenThree-drug regimenConventional intentionAntiretroviral regimenVirologic failureTreat comparisonProtocol deviationsRisk differenceTarget populationTreatment assignmentThree-drug armInverse probability weightsACTG A5095Protocol effectUS HIVHazard ratioRandomized trialsInverse oddsTreatment protocolRegimenUS individualsHIVProtocol estimatesTrialsProtocol analysis
2023
Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial
Zhang Y, Li J, Xie Y, Wu D, Ong J, Marley G, Kamarulzaman A, Lu H, Zou F, Smith J, Tucker J, Fu G, Tang W. Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial. Nature Medicine 2023, 29: 2241-2247. PMID: 37640859, DOI: 10.1038/s41591-023-02519-w.Peer-Reviewed Original ResearchConceptsHepatitis B virusCare armHCV testingVirus testingTwo-arm cluster-randomized trialHepatitis C virus testingHepatitis virus testingCluster-randomized trialProportion of menGroup of menAdverse eventsHBV testPrimary outcomeB virusForward armFree testingHCVMenRapid testingSexTrialsArmActive community participationTestingPersons